DexCom Inc (DXCM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DexCom Inc (DXCM) has a cash flow conversion efficiency ratio of 0.178x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($525.60 Million) by net assets ($2.96 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DXCM company net worth for the company's overall valuation and market capitalisation.
DexCom Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how DexCom Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DexCom Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DexCom Inc ranked by their cash flow conversion efficiency. Explore DexCom Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sandoz Group AG
SW:SDZ
|
0.094x |
|
Samsung SDI
KO:006400
|
-0.010x |
|
Ares Management LP
NYSE:ARES
|
0.048x |
|
Yuanta Financial Holdings Co Ltd
TW:2885
|
-0.059x |
|
Ameren Corp
NYSE:AEE
|
0.056x |
|
Heidelberg Materials AG
XETRA:HEI
|
0.169x |
|
TDK Corporation
F:TDKA
|
0.059x |
|
Kongsberg Gruppen ASA
OL:KOG
|
0.565x |
Annual Cash Flow Conversion Efficiency for DexCom Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of DexCom Inc from 2003 to 2025. View DexCom Inc (DXCM) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.75 Billion | $1.44 Billion | 0.525x | +11.48% |
| 2024-12-31 | $2.10 Billion | $989.50 Million | 0.471x | +30.06% |
| 2023-12-31 | $2.07 Billion | $748.50 Million | 0.362x | +15.22% |
| 2022-12-31 | $2.13 Billion | $669.50 Million | 0.314x | +44.93% |
| 2021-12-31 | $2.04 Billion | $442.50 Million | 0.217x | -16.78% |
| 2020-12-31 | $1.83 Billion | $475.60 Million | 0.260x | -26.93% |
| 2019-12-31 | $882.60 Million | $314.50 Million | 0.356x | +91.85% |
| 2018-12-31 | $663.30 Million | $123.20 Million | 0.186x | -15.33% |
| 2017-12-31 | $419.40 Million | $92.00 Million | 0.219x | +10.77% |
| 2016-12-31 | $283.80 Million | $56.20 Million | 0.198x | -10.61% |
| 2015-12-31 | $221.20 Million | $49.00 Million | 0.222x | +31.60% |
| 2014-12-31 | $140.20 Million | $23.60 Million | 0.168x | +489.86% |
| 2013-12-31 | $84.10 Million | $2.40 Million | 0.029x | +106.64% |
| 2012-12-31 | $77.00 Million | $-33.10 Million | -0.430x | -49.10% |
| 2011-12-31 | $104.49 Million | $-30.13 Million | -0.288x | +58.79% |
| 2010-12-31 | $60.99 Million | $-42.68 Million | -0.700x | -132.76% |
| 2009-12-31 | $-18.45 Million | $-39.39 Million | 2.135x | +120.17% |
| 2008-12-31 | $-38.61 Million | $-37.45 Million | 0.970x | +120.78% |
| 2007-12-31 | $7.12 Million | $-33.21 Million | -4.667x | -506.45% |
| 2006-12-31 | $56.83 Million | $-43.73 Million | -0.770x | -68.61% |
| 2005-12-31 | $49.41 Million | $-22.55 Million | -0.456x | -281.09% |
| 2004-12-31 | $-49.31 Million | $-12.43 Million | 0.252x | -13.15% |
| 2003-12-31 | $-32.60 Million | $-9.46 Million | 0.290x | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more